As generic entry looms for its cash cow, Jazz wins FDA nod for follow-up sleep disorder drug
After a 3-month delay attributed to labelling discussions, Jazz Pharmaceuticals $JAZZ has notched an approval for its wake-promoting drug solriamfetol, now christened Sunosi.
Like Xyrem — the blockbuster narcolepsy drug that accounts for the bulk of Jazz’s sales — Sunosi is designed to treat excessive daytime sleepiness for patients with obstructive sleep apnea (OSA) as well as narcolepsy. In 2018, Xyrem sales registered at $1.4 billion, translating to over 70% of total revenue. But with Sunosi in tow, total product sales are expected to jump substantially.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
